TNSN07070A1 - Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases - Google Patents
Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinasesInfo
- Publication number
- TNSN07070A1 TNSN07070A1 TNP2007000070A TNSN07070A TNSN07070A1 TN SN07070 A1 TNSN07070 A1 TN SN07070A1 TN P2007000070 A TNP2007000070 A TN P2007000070A TN SN07070 A TNSN07070 A TN SN07070A TN SN07070 A1 TNSN07070 A1 TN SN07070A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds
- inhibitors
- aminoheteroarylic
- kinases
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Abstract
Il est proposé des composés énantiomériquement pour de formule (I) : Ainsi que des procédés pour leur synthèse et des méthodes pour leur utilisation. Les composés préférés sont de puissants inhibiteurs de la protéine-kinase C- Met et sont utiles dans le traitement de troubles comportant la croissance cellulaire anormale, tels que les cancers.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60508604P | 2004-08-26 | 2004-08-26 | |
PCT/IB2005/002837 WO2006021884A2 (fr) | 2004-08-26 | 2005-08-15 | Composes d'aminoheteroaryle enantiomeriquement purs utilises comme inhibiteurs de proteine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN07070A1 true TNSN07070A1 (fr) | 2008-06-02 |
Family
ID=35967909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2007000070A TNSN07070A1 (fr) | 2004-08-26 | 2007-02-23 | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases |
Country Status (46)
Families Citing this family (169)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
NZ552946A (en) * | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
CN101023064B (zh) * | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
CA2632286C (fr) * | 2005-12-05 | 2011-11-15 | Pfizer Products Inc. | Utilisation de (r)-3-[1-(2,6-dichloro-3-fluro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine pour le traitement du cancer |
DK1963302T3 (da) * | 2005-12-05 | 2013-04-02 | Pfizer Prod Inc | Polymorfer af en C-MET/HGFR-inhibitor |
CA2646701A1 (fr) * | 2006-03-22 | 2007-10-04 | Vertex Pharmaceuticals Incorporated | Inhibiteurs de la c-met proteine kinase |
US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
EP3266867A1 (fr) | 2006-04-14 | 2018-01-10 | Cell Signaling Technology, Inc. | Défauts de gène et alk kinase mutante dans des tumeurs solides humaines |
WO2008021781A1 (fr) * | 2006-08-07 | 2008-02-21 | Incyte Corporation | Utilisation de triazolotriazines en tant qu'inhibiteurs des kinases |
GB0621607D0 (en) * | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
SI3034075T1 (sl) * | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8551995B2 (en) * | 2007-01-19 | 2013-10-08 | Xcovery Holding Company, Llc | Kinase inhibitor compounds |
AU2008239594B2 (en) | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
JP5973131B2 (ja) | 2007-09-13 | 2016-08-23 | コデクシス, インコーポレイテッド | アセトフェノンの還元のためのケトレダクターゼポリペプチド |
JP2011511005A (ja) * | 2008-02-04 | 2011-04-07 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 2−アミノピリジン系キナーゼ阻害薬 |
AR070317A1 (es) * | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
US20110039845A1 (en) | 2008-04-23 | 2011-02-17 | Kyowa Hakko Kirin Co., Ltd. | 2-aminoquinazoline derivative |
NZ589622A (en) | 2008-05-21 | 2012-10-26 | Incyte Corp | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
EP2143441A1 (fr) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
EP2356116A1 (fr) | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Pyrroloý2,3-b¨-pyridines et pyrroloý2,3-b¨-pyrazines substituées |
KR20110112352A (ko) | 2008-12-18 | 2011-10-12 | 노파르티스 아게 | 1-(4-{l-[(e)-4-시클로헥실-3-트리플루오로메틸-벤질옥시이미노]-에틸}-2-에틸-벤질)-아제티딘-3-카르복실산의 신규한 다형체 형태 |
JP5753093B2 (ja) | 2008-12-19 | 2015-07-22 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼのインヒビターとして有用なピラジン誘導体 |
EP3354643B1 (fr) | 2009-05-01 | 2020-10-28 | Aerie Pharmaceuticals, Inc. | Inhibiteurs à double mécanisme pour le traitement d'une maladie |
US9126931B2 (en) * | 2009-06-10 | 2015-09-08 | Chugai Seiyaku Kabushiki Kaisha | Tetracyclic compound |
DE102009056886A1 (de) | 2009-12-03 | 2011-06-09 | Bayer Schering Pharma Aktiengesellschaft | cMet-Inhibitoren zur Behandlung der Endometriose |
CA2788398C (fr) | 2010-02-03 | 2018-02-27 | Incyte Corporation | Imidazo[1,2-b][1,2,4]triazines en tant qu'inhibiteurs de c-met |
CA2796967C (fr) * | 2010-05-04 | 2015-12-01 | Pfizer Inc. | Derives heterocycliques destines au traitement de maladies |
CN103228651A (zh) | 2010-05-12 | 2013-07-31 | 沃泰克斯药物股份有限公司 | 可用作atr激酶抑制剂的化合物 |
WO2011143425A2 (fr) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Composés utilisables en tant qu'inhibiteurs de la kinase atr |
JP2013529200A (ja) * | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
EP3450432A1 (fr) | 2010-05-17 | 2019-03-06 | Incozen Therapeutics Pvt. Ltd. | Nouveaux composés 3,5 disubstitués-3h-imidazo[4,5-b] pyridine et 3,5-disubstitués-3h-[1,2,3]triazolo[4,5-b] pyridine utilisés comme modulateurs de kinases de protéine |
JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ |
EP3698788A1 (fr) | 2010-08-20 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Composition comprenant un composé tétracyclique |
WO2012042421A1 (fr) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Procédé de traitement de la croissance cellulaire anormale |
CN102464667B (zh) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | 一类五元杂环并嘧啶类化合物及其制备方法和用途 |
JP5965923B2 (ja) * | 2011-02-24 | 2016-08-10 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | プロテインキナーゼ阻害剤としてのリン含有化合物 |
US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
AU2012223281A1 (en) * | 2011-03-03 | 2013-09-19 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
CN102718745A (zh) * | 2011-03-30 | 2012-10-10 | 中国科学院上海药物研究所 | 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途 |
EP2710003A1 (fr) | 2011-05-16 | 2014-03-26 | OSI Pharmaceuticals, LLC | Inhibiteurs de kinases bicycliques fusionnés |
CN102850328B (zh) * | 2011-07-01 | 2014-12-24 | 苏州东南药业股份有限公司 | 吡啶类化合物、其制备方法、包含该化合物的药物组合物及其用途 |
EP2739284A1 (fr) | 2011-08-02 | 2014-06-11 | Pfizer Inc | Crizotinib pour l'utlisation dans le traitement de cancer |
EP2758387A4 (fr) * | 2011-09-21 | 2015-03-11 | Teligene Ltd | Composés de pyridine comme inhibiteurs de kinases |
IN2014CN02501A (fr) | 2011-09-30 | 2015-06-26 | Vertex Pharma | |
KR102184246B1 (ko) | 2011-09-30 | 2020-12-01 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 화합물의 제조 방법 |
CN103204844A (zh) * | 2012-01-17 | 2013-07-17 | 上海艾力斯医药科技有限公司 | 氨基杂芳基化合物及其制备方法与应用 |
CN104703598A (zh) | 2012-01-20 | 2015-06-10 | 奥克塞拉有限公司 | 用于疾病治疗的取代的杂环化合物 |
EP2620140A1 (fr) | 2012-01-26 | 2013-07-31 | ratiopharm GmbH | Compositions contenant crizotinibe |
PL2822953T3 (pl) | 2012-03-06 | 2017-07-31 | Pfizer Inc. | Makrocykliczne pochodne do leczenia chorób proliferacyjnych |
US9815831B2 (en) | 2012-03-30 | 2017-11-14 | Rhizen Pharmaceuticals Sa | 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo[4,5-B] pyridine compounds as modulators of c-Met protein kinases |
AU2013243291B2 (en) | 2012-04-05 | 2018-02-01 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and combination therapies thereof |
CN103373986B (zh) * | 2012-04-22 | 2016-10-05 | 东南大学 | 克里唑替尼前药及其制备方法与用途 |
CN103387535B (zh) * | 2012-05-10 | 2016-06-01 | 广东东阳光药业有限公司 | 取代的炔基吡啶化合物及其使用方法和用途 |
CN103420987B (zh) * | 2012-05-15 | 2015-11-25 | 上海医药工业研究院 | 吡啶衍生物及其制备方法 |
CN103420906B (zh) * | 2012-05-21 | 2015-09-09 | 南京圣和药业股份有限公司 | 新型酪氨酸蛋白激酶抑制剂 |
WO2013181251A1 (fr) | 2012-05-29 | 2013-12-05 | Ratiopharm Gmbh | Sel de chlorhydrate de crizotinib sous forme cristalline |
CN103509008A (zh) * | 2012-06-22 | 2014-01-15 | 康瑟特制药公司 | 吡唑取代的氨基-杂芳基化合物的衍生物 |
WO2013192512A1 (fr) * | 2012-06-22 | 2013-12-27 | Concert Pharmaceuticals, Inc. | Dérivés de composés amino-hétéroaryle substitués par un pyrazole |
WO2014020467A2 (fr) | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Procédé de préparation de composés d'aminohétéroaryle à substitution pyrazole |
US9446039B2 (en) | 2012-08-27 | 2016-09-20 | Cemm Forschungszentrum Für Molekulare Medizin Gmbh | Aminoheteroaryl compounds as MTH1 inhibitors |
US9651555B2 (en) | 2012-09-24 | 2017-05-16 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker |
CA2885722C (fr) | 2012-09-25 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteur de ret |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
WO2014081816A1 (fr) * | 2012-11-21 | 2014-05-30 | Concert Pharmaceuticals, Inc. | Dérivés fluorés de composés amino-hétéroaryle substitués par pyrazole |
CN104016979B (zh) * | 2012-11-23 | 2017-05-03 | 广东东阳光药业有限公司 | 取代的环化合物及其使用方法和用途 |
WO2014089324A1 (fr) * | 2012-12-07 | 2014-06-12 | Calitor Sciences, Llc | Composés cycliques substitués et leurs procédés d'utilisation |
CA2896187A1 (fr) * | 2013-01-18 | 2014-07-24 | F. Hoffmann-La Roche Ag | Pyrazoles 3 substitues et utilisation en tant qu'inhibiteurs de dlk |
WO2014115169A2 (fr) * | 2013-01-24 | 2014-07-31 | Hetero Research Foundation | Dispersion solide de crizotinib |
ES2716617T3 (es) * | 2013-02-02 | 2019-06-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhibidor de proteína quinasa de 2-aminopiridina sustituida |
WO2014139391A1 (fr) * | 2013-03-11 | 2014-09-18 | Teligene Ltd | Utilisation de composés de pyridine substituée en tant qu'inhibiteurs de kinases |
US20140275160A1 (en) | 2013-03-15 | 2014-09-18 | Aerie Pharmaceuticals, Inc. | Combination therapy |
WO2014203177A1 (fr) * | 2013-06-18 | 2014-12-24 | Shilpa Medicare Limited | (r)-3-[1-(2,6-dichloro-3-fluorophényl)méthoxy]-5-[1-(pipéridin-4-yl)-1h-pyrazol-4-yl]pyridine-2-amine amorphe |
CN104650049B (zh) * | 2013-08-28 | 2018-06-08 | 广东东阳光药业有限公司 | 取代的吡啶化合物及其使用方法和用途 |
WO2015034729A1 (fr) * | 2013-09-05 | 2015-03-12 | Calitor Sciences, Llc | Composés de pyridine substituée et leurs méthodes d'utilisation |
WO2015036898A2 (fr) * | 2013-09-10 | 2015-03-19 | Shilpa Medicare Limited | Nouveaux sels de crizotinib et leur préparation |
CA2924545C (fr) * | 2013-09-20 | 2022-12-06 | Biomarin Pharmaceutical Inc. | Inhibiteurs de la glucosylceramide synthase pour le traitement de maladies |
CN104513253A (zh) | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
EP3066118B1 (fr) | 2013-11-06 | 2020-01-08 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anticorps anti-alk, conjugues, et recepteurs antigeniques chimeriques, et leur utilisation |
CN103755627B (zh) * | 2014-01-09 | 2016-02-17 | 定陶县友帮化工有限公司 | 2-氨基-3-羟基-5-氯吡啶的合成方法 |
AU2015211119B2 (en) * | 2014-01-29 | 2019-05-30 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
JP6247992B2 (ja) * | 2014-04-17 | 2017-12-13 | 株式会社ダイセル | ハロゲン化合物の製造方法 |
JP6873698B2 (ja) | 2014-04-25 | 2021-05-19 | 中外製薬株式会社 | 4環性化合物の新規結晶 |
SG11201607623XA (en) | 2014-04-25 | 2016-11-29 | Chugai Pharmaceutical Co Ltd | Preparation containing tetracyclic compound at high dose |
ES2762641T3 (es) | 2014-07-31 | 2020-05-25 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Inhibidores de proteína quinasa de 2-aminopiridina sustituida con piridina |
TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體 |
CN105348265A (zh) * | 2014-08-19 | 2016-02-24 | 蔡苹 | 一种具有ALK和c-Met抑制活性的2,4-二取代杂环三氮唑类化合物的制备和应用 |
US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
CN105820113B (zh) * | 2015-01-07 | 2018-04-20 | 爱技特科技(北京)有限公司 | 一种克唑替尼手性中间体的制备方法 |
JP6741596B2 (ja) | 2015-01-16 | 2020-08-19 | 中外製薬株式会社 | 併用医薬 |
CN104693184A (zh) * | 2015-03-17 | 2015-06-10 | 安润医药科技(苏州)有限公司 | 克唑替尼的合成方法 |
AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
CA3000386A1 (fr) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combinaison d'un antagoniste de la liaison de l'axe pd-1 et d'un inhibiteur de alk dans le traitement du cancer alk-negatif |
EP3376870B1 (fr) * | 2015-11-17 | 2021-08-11 | Aerie Pharmaceuticals, Inc. | Procédé de préparation d'inhibiteurs de kinase et de leurs intermédiaires |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
AU2017266951B2 (en) | 2016-05-20 | 2021-05-27 | Biohaven Pharmaceutical Holding Company Ltd. | Use of Glutamate modulating agents with Immunotherapies to treat cancer |
CN106083708A (zh) * | 2016-06-30 | 2016-11-09 | 浙江大学 | 含2‑吡啶酮环侧链的2‑氨基吡啶衍生物及制备和应用 |
KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
KR20230150408A (ko) | 2016-12-22 | 2023-10-30 | 암젠 인크 | 폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체 |
CN106831720B (zh) * | 2017-01-21 | 2019-04-16 | 河北科技大学 | 双-4-(1h-吡唑-1-基)哌啶-1-甲酸叔丁酯的合成方法及其应用 |
KR20190135027A (ko) | 2017-03-31 | 2019-12-05 | 에어리 파마슈티컬즈, 인코포레이티드 | 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물 |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
TWI731264B (zh) | 2017-09-08 | 2021-06-21 | 美商安進公司 | Kras g12c抑制劑以及其使用方法 |
JP6635999B2 (ja) * | 2017-10-13 | 2020-01-29 | 株式会社ダイセル | カリウム塩の製造方法、及びカリウム塩 |
CN108191833A (zh) * | 2018-01-17 | 2018-06-22 | 浙江树人学院 | 克唑替尼衍生物及其制备方法和应用 |
CN110396088B (zh) * | 2018-04-25 | 2024-03-12 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂、制备方法及其应用 |
WO2019206049A1 (fr) * | 2018-04-25 | 2019-10-31 | Zhuhai Yufan Biotechnologies Co., Ltd | Inhibiteurs d'hpk1, procédé de préparation et utilisation associés |
CA3099118A1 (fr) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Inhibiteurs de kras g12c et leurs procedes d'utilisation |
JP7266043B2 (ja) | 2018-05-04 | 2023-04-27 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
MA52564A (fr) | 2018-05-10 | 2021-03-17 | Amgen Inc | Inhibiteurs de kras g12c pour le traitement du cancer |
JP7360396B2 (ja) | 2018-06-01 | 2023-10-12 | アムジエン・インコーポレーテツド | Kras g12c阻害剤及び同一物の使用方法 |
MX2020012204A (es) | 2018-06-11 | 2021-03-31 | Amgen Inc | Inhibidores de kras g12c para tratar el cáncer. |
US11285156B2 (en) | 2018-06-12 | 2022-03-29 | Amgen Inc. | Substituted piperazines as KRAS G12C inhibitors |
EP3848361A4 (fr) | 2018-09-04 | 2022-06-15 | Chugai Seiyaku Kabushiki Kaisha | Procédé de production de composé tétracyclique |
WO2020056345A1 (fr) | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Composés d'amide aryl cyclopropyl-amino-isoquinolinyl |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
MA55136A (fr) | 2018-11-19 | 2022-02-23 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MX2021007158A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
MA54550A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
BR112021011989A2 (pt) | 2018-12-20 | 2021-09-08 | Amgen Inc. | Inibidores de kif18a |
MX2021007157A (es) | 2018-12-20 | 2021-08-16 | Amgen Inc | Heteroarilamidas utiles como inhibidores de kif18a. |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
JP2022522777A (ja) | 2019-03-01 | 2022-04-20 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
CA3130083A1 (fr) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Composes heterocyclyle bicycliques et leurs utilisations |
EP3738593A1 (fr) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosage d'inhibiteur de kras pour le traitement de cancers |
JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
US20220281843A1 (en) | 2019-08-02 | 2022-09-08 | Amgen Inc. | Kif18a inhibitors |
EP4007638A1 (fr) | 2019-08-02 | 2022-06-08 | Amgen Inc. | Dérivés de pyridine en tant qu'inhibiteurs de kif18a |
CN114401953A (zh) | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
WO2021026098A1 (fr) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Inhibiteurs de kif18a |
CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
JP2022552873A (ja) | 2019-10-24 | 2022-12-20 | アムジエン・インコーポレーテツド | がんの治療におけるkras g12c及びkras g12d阻害剤として有用なピリドピリミジン誘導体 |
MX2022005053A (es) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Inhibidores de peque?as moleculas de mutante g12c de kras. |
JP2023515235A (ja) | 2019-10-31 | 2023-04-12 | 大鵬薬品工業株式会社 | 4-アミノブタ-2-エンアミド誘導体及びその塩 |
CA3159559A1 (fr) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Inhibiteurs de ras |
JP2022553858A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
JP2023500328A (ja) | 2019-11-08 | 2023-01-05 | レボリューション メディシンズ インコーポレイテッド | 二環式ヘテロアリール化合物及びその使用 |
BR112022009390A2 (pt) | 2019-11-14 | 2022-08-09 | Amgen Inc | Síntese melhorada de composto inibidor de kras g12c |
TW202132271A (zh) | 2019-11-14 | 2021-09-01 | 美商安進公司 | Kras g12c抑制劑化合物之改善的合成 |
JP2023505100A (ja) | 2019-11-27 | 2023-02-08 | レボリューション メディシンズ インコーポレイテッド | 共有ras阻害剤及びその使用 |
WO2021106231A1 (fr) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | Composé ayant une activité inhibitrice contre la mutation kras g12d |
JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ,インコーポレイテッド | Shp2阻害剤投薬およびがんを処置する方法 |
WO2021196655A1 (fr) * | 2020-04-03 | 2021-10-07 | 中国药科大学 | Composé contenant une structure benzimidazole, son procédé de préparation et application de celui-ci |
WO2021215545A1 (fr) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c |
EP4139299A1 (fr) | 2020-04-24 | 2023-03-01 | Taiho Pharmaceutical Co., Ltd. | Inhibiteurs de protéine kras g12d |
EP4168002A1 (fr) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Méthodes de retardement, de prévention et de traitement de la résistance acquise aux inhibiteurs de ras |
WO2022014640A1 (fr) | 2020-07-15 | 2022-01-20 | 大鵬薬品工業株式会社 | Combinaison contenant un composé pyrimidine destinée à être utilisée dans le traitement de tumeurs |
MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
CN114437058A (zh) * | 2020-10-30 | 2022-05-06 | 珠海宇繁生物科技有限责任公司 | 氘代hpk1激酶抑制剂及其制备方法和应用 |
EP4267250A1 (fr) | 2020-12-22 | 2023-11-01 | Qilu Regor Therapeutics Inc. | Inhibiteurs de sos1 et utilisations associées |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
WO2022235866A1 (fr) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Inhibiteurs de ras covalents et leurs utilisations |
BR112023022819A2 (pt) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Compostos, composição farmacêutica, conjugados e métodos para tratar câncer em um sujeito, para tratar um distúrbio e para inibir uma proteína ras em uma célula |
WO2022250170A1 (fr) | 2021-05-28 | 2022-12-01 | Taiho Pharmaceutical Co., Ltd. | Petites molécules inhibitrices de protéines mutées par kras |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (fr) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Composés pyrazolopyrazine utilisés comme inhibiteurs de la shp2 |
EP4227307A1 (fr) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2 |
WO2023172940A1 (fr) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Méthodes de traitement du cancer du poumon réfractaire immunitaire |
CN114767676B (zh) * | 2022-04-22 | 2024-04-19 | 珠海宇繁生物科技有限责任公司 | Hpk1激酶抑制剂在预防和/或治疗人的病原体感染中的应用 |
WO2023240263A1 (fr) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Inhibiteurs de ras macrocycliques |
WO2024081916A1 (fr) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Méthodes de traitement de cancers à l'aide de dérivés d'isoquinoline ou de 6-aza-quinoléine |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB129611A (en) | 1919-04-15 | 1919-07-17 | John Norman Riddell Hannam | Improvements in Stropping or Sharpening Devices for Safety Razor Blades. |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5587458A (en) * | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
DE69333807T2 (de) * | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
CA2218503C (fr) * | 1995-04-20 | 2001-07-24 | Pfizer Inc. | Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
KR100489174B1 (ko) | 1996-03-05 | 2005-09-30 | 제네카-파마 소시에떼아노님 | 4-아닐리노퀴나졸린유도체 |
AU2710597A (en) | 1996-06-27 | 1998-01-14 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
EP0818442A3 (fr) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
BR9710362A (pt) | 1996-07-13 | 1999-08-17 | Glaxo Group Ltd | Composto formula-ao farmaceutica utiliza-ao de um composto processos de tratamento de um ser humano ou animal sofrendo de uma mediada por atividade anormal de cinase de proteina tirosina e para a prepara-ao de um composto |
DE19628569A1 (de) | 1996-07-16 | 1998-01-22 | Bayer Ag | Substituierte N-(5-Isothiazolyl)-thioamide |
DE69712496T2 (de) | 1996-07-18 | 2002-08-29 | Pfizer | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
KR20000068248A (ko) | 1996-08-23 | 2000-11-25 | 디. 제이. 우드, 스피겔 알렌 제이 | 아릴설포닐아미노 하이드록삼산 유도체 |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
WO2000035298A1 (fr) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing-gum contenant des agents medicamenteux actifs |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
US6303636B1 (en) | 1997-02-03 | 2001-10-16 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
BR9807678A (pt) | 1997-02-11 | 2000-02-15 | Pfizer | Derivados de ácidos arilsulfonil-hidroxâmicos |
WO1998050356A1 (fr) | 1997-05-07 | 1998-11-12 | Sugen, Inc. | Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase |
EP0984692A4 (fr) | 1997-05-30 | 2001-02-21 | Merck & Co Inc | Nouveaux inhibiteurs d'angiogenese |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
CA2299355C (fr) * | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Derives de l'acide aryloxyarylsulfonylamino hydroxamique |
DE69838172T2 (de) | 1997-08-22 | 2008-04-10 | Astrazeneca Ab | Oxindolylchinazolinderivate als angiogenesehemmer |
JP2001518470A (ja) | 1997-09-26 | 2001-10-16 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成阻害剤 |
JP2001522853A (ja) | 1997-11-11 | 2001-11-20 | ファイザー・プロダクツ・インク | 抗癌剤として有用なチエノピリミジンおよびチエノピリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
DE69917124T2 (de) | 1998-04-10 | 2005-05-12 | Pfizer Products Inc., Groton | Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate |
WO1999061422A1 (fr) | 1998-05-29 | 1999-12-02 | Sugen, Inc. | Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
JP3494409B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗がん剤として有用なアルキニル置換キノリン−2−オン誘導体 |
PL346426A1 (en) | 1998-08-27 | 2002-02-11 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
EP1004578B1 (fr) | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | Dérivés d'hydroxamide de l'acide 5-oxo-pyrrolidine-2-carboxylique |
EP1006113A1 (fr) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
CA2356748A1 (fr) | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Procede d'utilisation d'un antagoniste de l'integrine et radiotherapie en tant que polytherapie dans le traitement des neoplasies |
US6649645B1 (en) | 1998-12-23 | 2003-11-18 | Pharmacia Corporation | Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia |
JP3270834B2 (ja) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | 抗がん剤として有用なヘテロ芳香族二環式誘導体 |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
IL144307A0 (en) | 1999-02-11 | 2002-05-23 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
US6511993B1 (en) * | 1999-06-03 | 2003-01-28 | Kevin Neil Dack | Metalloprotease inhibitors |
EP1081137A1 (fr) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite |
TR200400342T4 (tr) | 1999-11-30 | 2004-03-22 | Pfizer Products Inc. | Farnezil protein transferazı önlemek için kinolin türevleri. |
UA75055C2 (uk) * | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
ATE369359T1 (de) * | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
US6844357B2 (en) | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
SE0102438D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
SE0102439D0 (sv) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
WO2004004720A1 (fr) | 2002-07-03 | 2004-01-15 | Astex Technology Limited | 3-(hetero) arylmethoxy pyridines et leurs analogues en tant qu'inhibiteurs de la p38 map kinase |
SE0203754D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
CN1777427A (zh) * | 2003-02-26 | 2006-05-24 | 苏根公司 | 作为蛋白激酶抑制剂的氨基杂芳基化合物 |
ES2401330T3 (es) * | 2003-02-26 | 2013-04-18 | Sugen, Inc. | Compuesto de heteroarilamino inhibidores de proteín quinasas |
WO2005002673A1 (fr) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Inhibiteurs de raf kinase |
CA2578298A1 (fr) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Biotransformation par selection enantiomerique permettant la preparation de produits intermediaires inhibant la proteine tyrosine kinase |
JP2008510792A (ja) * | 2004-08-26 | 2008-04-10 | ファイザー・インク | タンパク質チロシンキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
NZ552946A (en) * | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
CN101023064B (zh) * | 2004-08-26 | 2011-02-16 | 辉瑞大药厂 | 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物 |
CA2632286C (fr) * | 2005-12-05 | 2011-11-15 | Pfizer Products Inc. | Utilisation de (r)-3-[1-(2,6-dichloro-3-fluro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1h-pyrazol-4-yl)-pyridin-2-ylamine pour le traitement du cancer |
DK1963302T3 (da) * | 2005-12-05 | 2013-04-02 | Pfizer Prod Inc | Polymorfer af en C-MET/HGFR-inhibitor |
-
2005
- 2005-08-15 CN CN2005800288183A patent/CN101023064B/zh active Active
- 2005-08-15 EP EP05779735.9A patent/EP1786785B9/fr active Active
- 2005-08-15 PT PT05779735T patent/PT1786785E/pt unknown
- 2005-08-15 WO PCT/IB2005/002837 patent/WO2006021884A2/fr active Application Filing
- 2005-08-15 GE GEAP20059887A patent/GEP20104906B/en unknown
- 2005-08-15 CA CA2578066A patent/CA2578066C/fr active Active
- 2005-08-15 EA EA200700352A patent/EA013678B1/ru active Protection Beyond IP Right Term
- 2005-08-15 JP JP2007529036A patent/JP4242911B2/ja active Active
- 2005-08-15 RS RSP-2010/0255A patent/RS51362B/en unknown
- 2005-08-15 UA UAA200701928A patent/UA87153C2/ru unknown
- 2005-08-15 KR KR1020077004393A patent/KR100859891B1/ko active IP Right Grant
- 2005-08-15 NZ NZ552866A patent/NZ552866A/en unknown
- 2005-08-15 AT AT05779735T patent/ATE463486T1/de active
- 2005-08-15 AU AU2005276135A patent/AU2005276135B2/en active Active
- 2005-08-15 MX MX2007002312A patent/MX2007002312A/es active IP Right Grant
- 2005-08-15 AP AP2007003888A patent/AP2373A/xx active
- 2005-08-15 DE DE602005020465T patent/DE602005020465D1/de active Active
- 2005-08-15 BR BRPI0513915-5A patent/BRPI0513915A/pt not_active Application Discontinuation
- 2005-08-15 PL PL05779735T patent/PL1786785T3/pl unknown
- 2005-08-15 ME MEP-2010-255A patent/ME01788B/me unknown
- 2005-08-15 ES ES05779735T patent/ES2341351T3/es active Active
- 2005-08-15 DK DK05779735.9T patent/DK1786785T3/da active
- 2005-08-15 BR BR122020017756-0A patent/BR122020017756B1/pt active IP Right Grant
- 2005-08-15 SI SI200531015T patent/SI1786785T1/sl unknown
- 2005-08-19 MY MYPI20053920A patent/MY145177A/en unknown
- 2005-08-23 UY UY29081A patent/UY29081A1/es active IP Right Grant
- 2005-08-23 AR ARP050103533A patent/AR050788A1/es active IP Right Grant
- 2005-08-24 PE PE2005000973A patent/PE20060501A1/es active IP Right Grant
- 2005-08-24 GT GT200500225A patent/GT200500225A/es unknown
- 2005-08-24 HN HN2005000476A patent/HN2005000476A/es unknown
- 2005-08-25 TW TW094129125A patent/TWI358406B/zh active
- 2005-08-25 NL NL1029799A patent/NL1029799C2/nl active Search and Examination
- 2005-08-26 US US11/212,331 patent/US7858643B2/en active Active
- 2005-08-26 PA PA20058643301A patent/PA8643301A1/es unknown
-
2007
- 2007-01-04 ZA ZA200700127A patent/ZA200700127B/xx unknown
- 2007-01-16 CR CR8860A patent/CR8860A/es unknown
- 2007-02-15 IL IL181384A patent/IL181384A/en active Protection Beyond IP Right Term
- 2007-02-23 NI NI200700057A patent/NI200700057A/es unknown
- 2007-02-23 TN TNP2007000070A patent/TNSN07070A1/fr unknown
- 2007-02-26 MA MA29720A patent/MA28828B1/fr unknown
- 2007-02-26 EC EC2007007276A patent/ECSP077276A/es unknown
- 2007-03-09 NO NO20071290A patent/NO333231B1/no active Protection Beyond IP Right Term
- 2007-10-04 HK HK07110739.8A patent/HK1105414A1/xx unknown
-
2010
- 2010-05-14 CY CY20101100430T patent/CY1110044T1/el unknown
- 2010-05-26 HR HR20100298T patent/HRP20100298T1/hr unknown
- 2010-09-01 US US12/874,073 patent/US20100324061A1/en not_active Abandoned
-
2012
- 2012-06-29 US US13/537,759 patent/US8785632B2/en active Active
-
2013
- 2013-02-20 LU LU92155C patent/LU92155I2/fr unknown
- 2013-03-06 FR FR13C0015C patent/FR13C0015I2/fr active Active
- 2013-04-15 NO NO2013008C patent/NO2013008I2/no not_active IP Right Cessation
- 2013-04-18 CY CY2013014C patent/CY2013014I1/el unknown
-
2014
- 2014-06-06 US US14/298,309 patent/US20140288086A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN07070A1 (fr) | Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases | |
TNSN07071A1 (fr) | Composes aminohetero-aryliques a substituant pyrazole servant d'inhibiteurs de proteine-kinases | |
JP6595565B2 (ja) | 免疫関連及び炎症性疾患の治療 | |
MA30232B1 (fr) | Inhibiteurs de kinase bases sur l'hydantoine | |
MA29772B1 (fr) | Benzimidazoles substitues et procedes de preparation | |
MA27334A1 (fr) | Utilisation d'inhibiteurs de l'ikb kinase dans le traitement de la douleur | |
MA30911B1 (fr) | Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine | |
TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
MA31419B1 (fr) | Derives de pyridine | |
EA200701239A1 (ru) | 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат | |
MA31949B1 (fr) | Dérivés d'aminotriazole comme agonistes d'alx | |
EA200600294A1 (ru) | [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении | |
MA31260B1 (fr) | 3-imidazolyl-indoles pour le traitement de maladies proliferatives | |
EA200601239A1 (ru) | Замещённые хинолиновые соединения | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
MA28562B1 (fr) | 1,3,4-oxadiazol-2-ones comme modulateurs de ppar delta et leur utilisation | |
MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
TNSN99031A1 (fr) | Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
MA30707B1 (fr) | DERIVES D'ISOSERINE DESTINES A ETRE UTILISES COMME INHIBITEURS DU FACTEUR DE COAGULATION Ixa. | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
MA32158B1 (fr) | Thiazolyldihydroindazoles | |
MA27905A1 (fr) | Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires | |
SE0302756D0 (sv) | Novel Compounds |